Healthcare Industry News: HSMN NewsFeed
News Release - March 8, 2021
Solta Medical Announces the U.S. Launch of The Clear + Brilliant(R) Touch LaserSystem Utilizes Two Wavelengths to Provide a Customizable and More Comprehensive Treatment Protocol for Patients of All Ages and Skin Types
LAVAL, QC, March 8, 2021 -- (Healthcare Sales & Marketing Network) -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its Solta Medical business, a global leader in the medical aesthetics market, today announced the U.S. launch of the Clear + Brilliant® Touch laser, the company's next generation Clear + Brilliant® laser. The Clear + Brilliant® Touch laser delivers a customized and more comprehensive treatment protocol by providing patients of all ages and skin types the benefits of two wavelengths. By seamlessly switching between two wavelengths with the Original and Perméa® handpieces, physicians can now more easily deliver a more complete treatment during a single appointment.
"The new innovative features of the Clear + Brilliant® Touch laser are designed to make the system easier and more convenient to use. Aesthetic providers can now more efficiently offer patients a complete treatment using two wavelengths by seamlessly switching between the Original and Perméa® handpieces during one appointment. We believe physicians and their patients will experience a real advantage with the new Clear + Brilliant® Touch laser," said Tom Hart, global vice president, Solta Medical. "As pioneers in the aesthetic market, Solta Medical has continued to evolve the Clear + Brilliant® technology to improve upon the efficiency and convenience that physicians and their patients have come to expect from Solta Medical."
In addition to offering easy access to both the Original and Perméa® handpieces in the compact system, the Clear + Brilliant® Touch laser also includes a user-friendly touchscreen, a simple training mode to simulate treatment without emitting laser energy and a smart charting assistant that automatically tracks treatment progress with the ability to export patient treatment charts.
"The Clear + Brilliant® laser is an easy-to-use and transportable system that has been a mainstay in my practice for years. The new system, the Clear + Brilliant® Touch laser offers even more versatility, for my patients. Having the option to use both wavelengths seamlessly during one appointment will be a welcome addition to my practice and to my patients," said Jeffrey S. Dover, M.D., FRCPC, a board-certified dermatologist in Boston, MA.
About the Clear + Brilliant® Laser
Solta Medical's Clear + Brilliant® laser, which has been a pioneer in preventative* skin treatments and a leader in the laser treatment landscape since 2011, has delivered more than 2.5 million procedures. Supported by robust evidence-based data that includes more than 15 clinical studies, the Clear + Brilliant® laser uses fractional laser technology to create structural and functional changes to the skin, helping to prevent* the early signs of aging, maintain youthful looking skin and improve the skin's overall appearance.
For more information on the Clear + Brilliant® Touch laser, visit www.touch.clearandbrilliant.com/hcp.
About Solta Medical
Solta Medical, part of the Ortho Dermatologics business of Bausch Health Companies Inc., is a global leader in the medical aesthetics market that helps drive revenue growth to aesthetic practices by providing innovative and effective skin rejuvenation and body contouring solutions. Solta Medical's vision is to develop and support trusted aesthetic brands that provide value and lasting growth to physicians and patients. These include the Thermage® RF systems, Fraxel® laser, Clear + Brilliant® laser and VASER® ultrasonic systems. More than six million procedures have been performed with Solta Medical's portfolio of products around the world. More information can be found at www.solta.com.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
®/TM are trademarks of Bausch Health Companies Inc. or its affiliates. Any other product/brand names and/or logos are trademarks of the respective owners.
© 2021 Bausch Health Companies Inc. or its affiliates.
*Preventative treatment refers to prevention of worsening of fine lines or wrinkles due to aging or sun damage.
Source: Bausch Health Companies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.